Neurimmune presented at Life Science Zurich Impact - "The Cause of Health" new data on NI006, a human antibody in development for the treatment of ATTR cardiomyopathy. #Neurimmune #LSZIMPACT

We are pleased to announce initiation of a Phase 1 study of #NI006 for the treatment of ATTR cardiomyopathy: bit.ly/32vLKoB #antibody #amyloid #ATTR #amyloidosis #cardiomyopathy

We will be attending upcoming digital meetings #BioEuropeSpring and #AATADPD. We look forward to e-meet you there! #Neurimmune neurimmune.com

We are pleased to announce a collaboration agreement with @Ethris_mRNA to rapidly develop an inhaled mRNA-based antibody therapy for the #treatment of #COVID19: bit.ly/2R3co3w

Today, Biogen completed submission of a BLA filing to U.S. FDA for review of our investigational drug for #Alzheimer’s disease. If approved, this would be the first drug with potential to meaningfully change the course of Alzheimer’s disease.

We are proud to collaborate with Biogen on aducanumab and welcome today's news about the completion of the BLA filing. bit.ly/2BP9j2N #biogen #neurimmune #aducanumab #alzheimersdisease

We welcome Biogen’s news on FDA’s acceptance of the aducanumab BLA filing with priority review. #aducanumab #Alzheimer #Neurimmune #Biogen bit.ly/2F4pFWJ

We just published our NI006 preclinical work. The human antibody NI006 is currently investigated in Phase 1 for the treatment of ATTR cardiomyopathy. go.nature.com/3wBMxSI #Neurimmune #ATTR #amyloidosis

Today we shared ground-breaking new data at #CTAD21 from our ongoing research efforts in #AlzheimersDisease. Read our news release:

Today, Neurimmune and TVM announced the initiation of Phase 2 clinical development of AP-101 for the treatment of ALS. TVM Capital Life Science #neurimmune #ALS bit.ly/3CwW4gm

We are excited to announce our collaboration with AstraZeneca to develop and commercialize NI006, an investigational human monoclonal antibody targeting TTR amyloid. #Neurimmune #Alexion #AstraZeneca #ATTR #cardiomyopathy Learn more: bit.ly/3JM6JIZ

.AstraZeneca and Neurimmune sign deal for NI006. Read more: bit.ly/3HJX580

We are excited to expand our long-term trusted partnership with Ono in the field of neurodegenerative diseases. #Neurimmune #OnoPharma #RTM #ReverseTranslationalMedicine Find out more: bit.ly/3twZdft

We are looking forward to attending CTAD next week in San Francisco. Roger M. Nitsch will be presenting a keynote lecture on the “Therapeutic Reversal of Amyloid and Tau Pathology in Alzheimer’s Disease” on Dec 2. bit.ly/3Ew02ZM #CTAD #AlzheimersDisease #Neurimmune

Today, primary results of the Phase 1b proof-of-concept study of NI006 will be presented at Heart Failure 2023, a scientific congress of the European Society of Cardiology, on May 20, 4:40 pm CEST. Stay tuned. #ATTR #amyloidosis #HeartFailure2023 bit.ly/3MqwlNE

We just published the results of our Phase 1 proof-of-concept study of NI006 in The New England Journal of Medicine. Read more: bit.ly/42Urqf4 #ATTRcardiomyopathy #HeartFailure2023 #nejm #amyloidosis #neurimmune